Home › Type 2 Diabetes › NCT07590193

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Who can join

Ages 18 to 75 · All sexes · Healthy volunteers welcome

Inclusion Criteria for Part A and B

* Participant must be 18-65 years of age
* Participant must be overtly healthy

Inclusion Criteria for Part C

* Participant must be 40-75 years of age
* Confirmed diagnoses of T2DM

Exclusion Criteria for Part A and B

* History of hypotension, syncope, or orthostatic intolerance
* Systolic blood pressure \>140 millimeters of mercury (mmHg) or diastolic blood pressure \>90 mmHg

Exclusion Criteria for Part C

* Hemoglobin A1c (HbA1c) \>10% within the last 3 months
* History of hypotension, syncope, or orthostatic intolerance
* Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg

About the study

The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).

What is being tested

• AMG 127 (drug)
• Placebo (drug)

Sponsor: Amgen · Participants: 162 · Started: Jun 11, 2026

Contact the study team

• Amgen Call Center · Phone: 866-572-6436

Official record on ClinicalTrials.gov — NCT07590193

Locations in the U.S.

Conditions

• Type 2 Diabetes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.